{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:44:46Z","timestamp":1753357486699,"version":"3.32.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1038\/sj.bjc.6602909","type":"journal-article","created":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T18:12:13Z","timestamp":1136916733000},"page":"62-68","source":"Crossref","is-referenced-by-count":11,"title":["SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel\u2013gemcitabine as first-line chemotherapy for ovarian cancer"],"prefix":"10.1038","volume":"94","author":[{"given":"P A","family":"Vasey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Symonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Lewsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N S","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J S","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,11]]},"reference":[{"key":"BF6602909_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures 2004 (2004). Atlanta, GA: American Cancer Society"},{"key":"BF6602909_CR2","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.bjc.6601697","volume":"90","author":"C Barlow","year":"2004","unstructured":"Barlow C, Nystrom M, Oesterling C, Fennell D, Ismay J, Gallagher C (2004) Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br J Cancer 90: 1318\u20131322","journal-title":"Br J Cancer"},{"key":"BF6602909_CR3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57: 289\u2013300","journal-title":"J Roy Statist Soc Ser B"},{"key":"BF6602909_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0090-8258(03)00138-0","volume":"89","author":"A Berkenblit","year":"2003","unstructured":"Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA (2003) Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of m\u00fcllerian origin. Gynecol Oncol 89: 486\u2013493","journal-title":"Gynecol Oncol"},{"issue":"Suppl","key":"BF6602909_CR5","doi-asserted-by":"publisher","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21 (Suppl): 149s\u2013167s","journal-title":"J Clin Oncol"},{"key":"BF6602909_CR6","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748\u20131756","journal-title":"J Clin Oncol"},{"key":"BF6602909_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002800050723","volume":"41","author":"J Cassidy","year":"1998","unstructured":"Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 41: 161\u2013166","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6602909_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2","volume":"92","author":"G Cassinelli","year":"2001","unstructured":"Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F (2001) A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92: 738\u2013747","journal-title":"Int J Cancer"},{"key":"BF6602909_CR9","first-page":"169","volume":"37","author":"C Chantler","year":"1969","unstructured":"Chantler C, Garnett ES, Parsons V, Veall N (1969) Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci 37: 169\u2013180","journal-title":"Clin Sci"},{"key":"BF6602909_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","volume":"37","author":"A Cull","year":"2001","unstructured":"Cull A, Howat S, Greimel E, Waldenstrom AC, Arraras J, Kudelka A, Chauvenet L, Gould A, on behalf of the EORTC Quality of Life Group (European Organization for Research and Treatment of Cancer) and the Scottish Gynaecological Cancer Trials Group (2001) Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37: 47\u201353","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"BF6602909_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.9-suppl_2-3","volume":"9","author":"J Gligorov","year":"2004","unstructured":"Gligorov J, Lotz J-P (2004) Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 (Suppl 2): 3\u20138","journal-title":"Oncologist"},{"issue":"Suppl 3","key":"BF6602909_CR12","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/sj.bjc.6601496","volume":"89","author":"JP Guastalla III","year":"2003","unstructured":"Guastalla III JP, Dieras V (2003) The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 89 (Suppl 3): S16\u2013S22","journal-title":"Br J Cancer"},{"key":"BF6602909_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/sj.bjc.6601618","volume":"90","author":"AE Guppy","year":"2004","unstructured":"Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ (2004) A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer 90: 810\u2013814","journal-title":"Br J Cancer"},{"issue":"1 Suppl 1","key":"BF6602909_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sonc.2002.31593","volume":"29","author":"SW Hansen","year":"2002","unstructured":"Hansen SW (2002) Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 29 (1 Suppl 1): 17\u201319","journal-title":"Semin Oncol"},{"key":"BF6602909_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bjc.6602000","volume":"91","author":"M Harries","year":"2004","unstructured":"Harries M, Moss C, Perren T, Gore M, Hall G, Everard M, A'Hern R, Gibbens I, Jenkins A, Shah R, Cole C, Pizzada O, Kaye S (2004) A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 91: 627\u2013632","journal-title":"Br J Cancer"},{"key":"BF6602909_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.coc.0000045849.95834.6B","volume":"27","author":"Y Hsu","year":"2004","unstructured":"Hsu Y, Sood AK, Sorosky JI (2004) Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case\u2013control analysis of toxicity. Am J Clin Oncol 27: 14\u201318","journal-title":"Am J Clin Oncol"},{"key":"BF6602909_CR17","doi-asserted-by":"crossref","unstructured":"International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505\u2013515","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"BF6602909_CR18","first-page":"449","volume":"22","author":"GC Jayson","year":"2003","unstructured":"Jayson GC, Maenpaa J, Wilkinson PM, Ledermann JA, Welch RS, Cruickshank D, Chan S, Hindley A, Vasey PA, Fernebro E (2003) Randomized feasibility study of carboplatin followed by docetaxel or docetaxel\/irinotecan in ovarian cancer (SCOTROC IIB). Proc Am Soc Clin Oncol 22: 449 (Abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602909_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1525-1438.2000.99506.x","volume":"10","author":"SB Kaye","year":"2000","unstructured":"Kaye SB (2000) Intravenous chemotherapy for ovarian cancer \u2013 the state of the art? Int J Gynecol Cancer 10: 19\u201325","journal-title":"Int J Gynecol Cancer"},{"key":"BF6602909_CR20","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1200\/JCO.2000.18.23.3936","volume":"18","author":"C Lavarino","year":"2000","unstructured":"Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F (2000) p53 gene status and response to platinum\/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18: 3936\u20133945","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"BF6602909_CR21","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1038\/sj.bjc.6601498","volume":"89","author":"JU M\u00e4enp\u00e4\u00e4","year":"2003","unstructured":"M\u00e4enp\u00e4\u00e4 JU (2003) Docetaxel: promising and novel combinations in ovarian cancer. Br J Cancer 89 (Suppl 3): S29\u2013S34","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"BF6602909_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1525-1438.2003.13351.x","volume":"13","author":"FM Muggia","year":"2003","unstructured":"Muggia FM (2003) Sequential single agents as first line chemotherapy for ovarian cancer: a strategy derived from the results of GOG132. Int J Gyn Cancer 13 (Suppl 2): 156\u2013162","journal-title":"Int J Gyn Cancer"},{"key":"BF6602909_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","volume":"18","author":"FM Muggia","year":"2000","unstructured":"Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18: 106\u2013115","journal-title":"J Clin Oncol"},{"key":"BF6602909_CR24","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1023\/A:1008343519687","volume":"11","author":"CJ Poole","year":"2000","unstructured":"Poole CJ, Perren T, Burton A, Jordan SD, Jenkins AH, Mould JJ, Spooner DA, Luesley D, Chan KK, Sturman S, Earl HM (2000) Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer. Ann Oncol 11: 1603\u20131608","journal-title":"Ann Oncol"},{"key":"BF6602909_CR25","first-page":"2984","volume":"7","author":"A Reles","year":"2001","unstructured":"Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984\u20132997","journal-title":"Clin Cancer Res"},{"key":"BF6602909_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","volume":"7","author":"GJS Rustin","year":"1996","unstructured":"Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE (1996) Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7: 361\u2013364","journal-title":"Ann Oncol"},{"key":"BF6602909_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/S0959-8049(00)00341-5","volume":"36","author":"AL Thomas","year":"2000","unstructured":"Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S, O'Byrne KJ (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I\/II dose-escalating study. Eur J Cancer 36: 2329\u20132334","journal-title":"Eur J Cancer"},{"key":"BF6602909_CR28","first-page":"3957","volume":"20","author":"A Tognoni","year":"2000","unstructured":"Tognoni A, Pronzato P, Cadenotti L, Ghio E, Manna N, Pensa F, Marino L (2000) Sequential high dose-density chemotherapy in advanced ovarian cancer. Anticancer Res 20: 3957\u20133961","journal-title":"Anticancer Res"},{"key":"BF6602909_CR29","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, the Scottish Gynaecological Cancer Trials Group (2004) Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682\u20131691","journal-title":"J Natl Cancer Inst"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602909.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602909","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602909.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T01:30:59Z","timestamp":1736213459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["BF6602909"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602909","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}